EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 384 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia September 16, 2020 10-Year Data Underscore How ICI Therapy Has Helped to Change the... October 10, 2024 New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer... May 9, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab May 17, 2022 Load more HOT NEWS Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug... Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days... Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and...
